Manganese-enriched nanoboron agent amplifies BNCT efficacy via pyroptosis-mediated immune activation and STING pathway synergy​ Authors: Zhicheng Zhang, Xiaoyan Sun, Yaxin Qin, Yufan Yang, Qi Dai, Xiaoyan Bao, Minoru Suzuki, Sheng Wang, Zai Yang, Zhifeng Li, Min Han, Donghang Xu, Qichun Wei Published: 2025 ABSTRACT AbstractBoron Neutron Capture Therapy (BNCT) offers selective tumor cell ablation with minimal damage to normal tissues, but its efficacy is limited by therapy-induced immunosuppression and high intratumoral H2O2 levels, restricting synergy with immunotherapy. Here, we report BSA-BPA-MnO2, a tumor microenvironment-responsive, manganese-enriched nanoboron agent designed to overcome these barriers. This nanoplatform combines efficient boron delivery with Mn2+-driven Fenton-like catalysis and cGAS-STING pathway activation, amplifying BNCT-induced oxidative stress and inducing immunogenic pyroptosis alongside robust type I interferon signaling. This dual mechanism transforms BNCT from a local therapy into a systemic immune activator, enhancing dendritic cell maturation and CD8+ T cell responses. Additionally, MnO₂ enables MRI-guided BNCT, integrating diagnostics and therapeutics. Notably, the platform achieves potent tumor suppression and systemic immune activation even at subclinical boron levels, offering a promising strategy for next-generation immune-integrated BNCT, particularly against melanoma.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s12951-025-03916-8. Introduction Recent preclinical and clinical trial studies have shown that tumor radiation therapy (RT) can inherently generate damage-associated molecular patterns (DAMPs), which may trigger systemic anti-cancer adaptive immune responses [1–3]. RT-induced DAMPs employ localized treatment at the lesion site to induce immunogenic cell death (ICD), releasing tumor-associated antigens (TAAs) and immune adjuvants to initiate a systemic anti-cancer immune response [4, 5]. However, despite more than 500 clinical trials investigating the synergy between oncological radiation therapy and immunotherapy, most have not demonstrated positive interactions [6]. This is primarily because RT can also induce immune suppression [7, 8]. RT often increases hydrogen peroxide (H2O2) levels within tumor tissues, exacerbating intrinsic hypoxia and significantly reducing TAA release, which is one of the key reasons for immune suppression [9, 10]. Another reason for immune suppression is that most radiation therapies inevitably damage the effector immune cells within the tumor [11–13]. Boron Neutron Capture Therapy (BNCT) is a binary biologically targeted radiation therapy technology based on nuclear capture and fission reactions [14]. It uses the capture reaction between thermal neutrons and the non-radioactive10B isotope to produce high linear energy transfer (LET) α particles, 7Li nuclei, and γ rays [15]. The range of these high LET particles is 5–9 μm, limited to the diameter of a single cell [16, 17]. BNCT can selectively target tumor cells while sparing nearby normal cells, including effector immune cells [18]. Therefore, combining BNCT with immunotherapy may produce an efficient synergistic effect. Although evidence suggests that BNCT can effectively drive ICD, there is a lack of effective induction of type I interferons (IFN), which are essential for cross-presentation of TAAs to promote protective anti-tumor CD8+ T cell immunity [19–21]. Type I IFNs bridge innate and adaptive immune responses, with the cGAS-STING pathway playing a central role in this process by directly driving IFN secretion upon DNA damage [22]. Activating the cGAS-STING pathway effectively promotes TAAs cross-presentation, thereby enhancing systemic anti-tumor immune responses [22]. Therefore, a key challenge in enhancing BNCT efficacy is the development of a multifunctional boron drug capable of efficiently delivering 10B while simultaneously activating the cGAS-STING pathway to synergize with immunotherapy. Currently, two 10B formulations are in clinical trials. Sodium mercaptododecaborate (BSH) is a highly hydrophilic anionic boron cluster used for treating malignant brain tumors, while 4-Borono-L-phenylalanine (BPA) is a hydrophobic tyrosine analog used for treating malignant melanoma [17, 23, 24]. However, due to the low molecular weight (LMW) of these 10B formulations, they are rapidly cleared from the circulatory system after administration [25]. To improve tumor targeting and retention, several strategies have been explored, such as albumin-based nanoparticles, which are biocompatible, biodegradable, and capable of accumulating at tumor sites due to the enhanced permeability and retention (EPR) effect [26]. Albumin enhances the solubility of hydrophobic molecules like BPA in the blood and serves as a carrier to target tumors [27]. Recent studies have shown that Mn2+, released from membrane-bound organelles during viral infections, can directly bind to cGAS, triggering the cGAS-STING pathway and improving type I IFN secretion [28, 29]. This enhances dendritic cell (DC) maturation and promotes TAA presentation, thus strengthening the anti-cancer immune response [30]. Furthermore, Mn2+-catalyzed Fenton-like reactions can convert H2O2 induced by γ rays in BNCT into hydroxyl radicals (•OH), creating a ROS storm and further inducing pyroptosis in tumor cells, which is a highly immunogenic form of cell death [31–33]. This process mediates the release of large amounts of tumor antigens and inflammatory signaling molecules, synergistically triggering a potent anti-tumor immune response with BNCT [34]. Additionally, Mn2+ improves tumor T1-MRI imaging performance for tumor diagnosis [35]. In this work, we report a tumor microenvironment (TME)-responsive, manganese-enriched multifunctional nanoboron drug (BSA-BPA-MnO2) for BNCT and immunotherapy combination (Scheme 1a). BSA-BPA-MnO₂ remains stable at physiological pH (7.4) and releases Mn2+ in the acidic tumor microenvironment, guiding thermal neutron irradiation through MRI imaging. Following BNCT treatment, LET α particles and 7Li nuclei precisely kill tumor cells, triggering TAA release. Due to abnormal metabolism and high H2O2 levels induced by γ rays in the tumor region, Mn2+ catalyzes a Fenton-like reaction, generating •OH and amplifying oxidative stress, inducing highly immunogenic pyroptosis. The Mn2+ released from BSA-BPA-MnO2 can further activate the cGAS-STING pathway, promoting type I IFN secretion and enhancing in situ cancer vaccination (ISCV) effects. The BNCT and immunotherapy combination boosted by BSA-BPA-MnO2 effectively enhances CD8+ T cell-dependent anti-tumor immunity, improving the treatment efficacy for primary melanoma. Schematic Illustration of the BSA-BPA-MnO2 for Cancer Immunotherapy: (a) Procedure for the Preparation of BSA-BPA-MnO2 and the pH-Activatable Release in Tumor Tissue and (b) Therapeutic Mechanism of BSA-BPA-MnO2 via BNCT Inducing ICD and STING Pathway Activation Results and discussion Preparation and characterization of BSA-BPA-MnO2 A methanol solution containing boron-10 enriched BPA (10BPA) was added dropwise to a BSA solution to obtain BSA-10BPA nanoparticles, which were stabilized by crosslinking with glutaraldehyde. The purified BSA-10BPA was then treated with Mn2+ and adjusted to the appropriate pH, allowing MnO2 to deposit onto the surface, resulting in the manganese-enriched BSA-10BPA-MnO2 multifunctional nanoboron drug. Dynamic light scattering (DLS) analysis showed that the hydrodynamic diameter of BSA-10BPA was approximately 175 nm, while BSA-10BPA- MnO2 had a hydrodynamic diameter of approximately 182 nm (Fig. 2a). Both BSA-10BPA and BSA-10BPA-MnO2 exhibited negative charges, with ζ potentials of −24.6 mV and − 18.6 mV, respectively (Fig. 2b). Transmission electron microscopy (TEM) images showed that both BSA-10BPA and BSA-10BPA- MnO2 were smooth and spherical in shape (Fig. 2c). The XRD spectra of BSA protein, BSA-10BPA, and BSA-10BPA- MnO2 are shown in Fig. 2d. The broad peak of BSA protein indicates its amorphous nature, while the XRD spectrum of BSA-10BPA nanoparticles showed characteristic peaks at 2θ values of 20.9°, 23.4°, 25.6°, and 29.9°. The characteristic peaks disappeared for BSA-10BPA- MnO2due to the surface coverage of MnO2, which resulted in a flatter broad peak. As shown in Fig. 2e and Figures S1-S2, the X-ray photoelectron spectroscopy (XPS) spectrum of BSA-10BPA- MnO2 revealed characteristic peaks for B 1 s, C 1 s, N 1 s, O 1 s, and Mn 2p. The Mn 2p spectrum showed a main peak at 641.23 eV with a 2p peak separation of 11.7 eV, indicating the presence of MnO2 (Figure S2). In contrast, the XPS spectrum of BSA-10BPA, aside from the B 1 s, C 1 s, N 1 s, and O 1 s peaks, did not show a prominent Mn 2p feature (Figures S3-S4). Figure 2f shows that as the H2O2 concentration increased, the UV-Vis absorbance of BSA-10BPA-MnO2 gradually decreased. This suggests that in acidic media (pH = 6.8), H2O2 can decompose the MnO2 on the surface of BSA-10BPA- MnO2, releasing colorless Mn2+ ions and leading to a decrease in MnO2. Characteristics of BSA-10BPA-MnO2. (a) Dynamic light scattering (DLS) size of BSA-10BPA and BSA-10BPA-MnO2. (b) ζ potential of BSA-10BPA and BSA-10BPA-MnO2. (c) TEM images of BSA-10BPA and BSA-10BPA-MnO2. Scale bar: 200 nm. (d) XRD spectra of BSA, BSA-10BPA and BSA-10BPA-MnO2. (e) XPS spectra of BSA-10BPA-MnO2. (f) UV-Vis absorption spectra of BSA-10BPA-MnO2 (300 µM MnO2) pretreated with different concentrations of H2O2 (0, 50, 100, 150, 200, and 300 µM) Cellular uptake, cytotoxicity, and in vitro BNCT effect of BSA-10BPA-MnO2 The application of BNCT in cancer therapy requires selective boron uptake by tumor cells of at least 20 µg of boron per gram of tumor tissue, which corresponds to 109 boron atoms per cell (approximately 16.67 ng B/106 cells) [36]. Albumin, a non-specific transport protein, can target tumor cells. Tumor cells, due to their rapid proliferation, require large amounts of nutrients, and albumin can provide amino acids and energy through the albumin receptor Gp60 on the surface of tumor cells. The transport capacity of albumin, along with its biocompatibility, non-immunogenicity, and biodegradability, makes it a suitable carrier for targeted drug delivery [37]. Therefore, to assess boron delivery to tumor cells, we further measured the intracellular boron concentration by Inductively coupled plasma mass spectrometry (ICP-MS). As shown in Fig. 3a, after incubation with BSA-10BPA and BSA-10BPA-MnO2 for 4 h, the 10B uptake in B16F10 cells was 210.51 and 202.10 ng/106 cells, respectively. BPA, a boron-containing amino acid derivative, is transported into tumor cells via the amino acid transporter LAT-1 on the cell surface [38]. Using the BPA-fructose complex solution, which is clinically used in BNCT, as a control, the 10B uptake in cells was 182.77 ng/106 cells. These results indicate that the nanoparticle boron drugs, BSA-10BPA and BSA-10BPA-MnO2, effectively deliver boron to tumor cells via the Gp60 receptor, with transport efficiency comparable to BPA, fulfilling clinical requirements. The transport efficiency of this multifunctional nanoboron drug was also confirmed in the human glioblastoma cell line U87-MG (Figure S5). In vitro evaluation of the intracellular uptake, biocompatibility, and BNCT effect of BSA-10BPA-MnO2. (a) Quantitative analysis of 10B uptake in B16F10 cells after 4 h of treatment with different formulations (n = 4). (b) Evaluation of B16F10 cell viability (CCK-8 assay) after 24 h of treatment with different formulations (n = 6). (c) Representative images of colony formation in B16F10 cells after treatment with different formulations and BNCT. (d) Colony count statistics of B16F10 cells after treatment with different formulations and BNCT (n = 3). Data are presented as mean ± SD. *** p < 0.001, **** p < 0.0001 Next, we evaluated the biocompatibility of the multifunctional nanoboron drug in vitro. After incubating B16F10 cells (Fig. 3b) and U87-MG cells (Figure S6) with different concentrations of BPA-fructose complex (BPA-F), BSA-10BPA and BSA-10BPA-MnO2 for 24 h, no significant decrease in cell viability was observed, indicating that the nanoboron drug has high biocompatibility and no potential cytotoxicity. To assess the long-term cytotoxic effect of BSA-10BPA-MnO2 following BNCT treatment, colony formation assays were performed to evaluate the inhibitory effect of neutron irradiation on tumor cell growth in different treatment groups. The 1 Gy dose was selected based on previous BNCT studies that demonstrate effective tumor cell killing with minimal normal tissue damage [39]. This dose corresponds to the physical absorbed dose from the neutron beam, and the boron neutron capture dose is additional. As shown in Fig. 3c and d, following BNCT treatment with accelerator neutron beams (N), the number of B16F10 cell colonies significantly decreased for both BSA-10BPA and BSA-10BPA-MnO2, with the BSA-10BPA-MnO2 group exhibiting the strongest growth inhibition, with colony numbers only about half of those in the BPA-F irradiated group. We also assessed the effect of BSA-10BPA-MnO2 in U87-MG cells after exposure to reactor neutron source BNCT, as shown in Figure S7. After 30 min of irradiation with the reactor neutron source, both BSA-10BPA and BSA-10BPA-MnO2 groups showed almost no cell colonies, indicating significant tumor cell killing. Pyroptosis induced by BSA-10BPA-MnO2 after BNCT The tumor microenvironment (TME) is characterized by mild acidity and high H2O2 concentration, and the γ-rays generated by BNCT further exacerbate the production of H2O2, leading to locally high concentrations of H2O2 in the tumor [40]. Previous studies have shown that Mn2+ can generate •OH in the tumor environment through Fenton and Fenton-like reactions [41]. The accumulation of •OH can trigger pyroptosis through the caspase-1/gasdermin D (GSDMD) pathway, resulting in cell membrane swelling and the release of damage-associated molecular patterns (DAMPs) and inflammatory cytokines [42, 43]. To confirm whether the manganese-enriched nanoboron drug BSA-10BPA-MnO2 can drive the generation of high levels of ROS, such as •OH, after BNCT, we used 2,7-dichlorofluorescin diacetate (DCFH-DA) as a probe to monitor ROS levels in B16F10 cells. Compared to BNCT treatment alone, higher levels of ROS were observed in B16F10 cells after incubation with BPA-F, BSA-10BPA, and BSA-10BPA-MnO2 followed by neutron irradiation, with the BSA-10BPA-MnO2 + N group showing the most prominent green fluorescence (Fig. 4a). These results indicate that boron-containing drugs induce ROS production after BNCT, and the Mn2+ released from BSA-10BPA-MnO2 at the tumor site drives an ROS storm through the Fenton reaction. Pyroptosis Induced by BSA-10BPA-MnO2 after BNCT. (a) Fluorescent images of ROS in B16F10 cells after different treatments, detected by DCFH-DA staining. Scale bar: 150 μm. (b) Cell morphology images after different treatments. In the BSA-10BPA-MnO2 + N group, cell swelling and the appearance of large bubbles (blue arrows, one of the most prominent features of pyroptosis) are observed. Scale bar: 50 μm. (c) Western blot analysis of caspase-1 (CAS-1) and cleaved caspase-1 (cleaved-CAS-1). (d) Immunofluorescent staining of the GSDMD protein N-terminal fragment (GSDMD-N). Scale bar: 100 μm. (e) Relative LDH release, n = 4. Data are presented as mean ± SD. * p < 0.5, **** p < 0.0001 Pyroptosis is a unique form of programmed cell death characterized by membrane perforation, cell swelling, and the formation of large bubbles [44]. Notably, typical membrane swelling was observed in B16F10 cells treated with BSA-10BPA-MnO2 + N, but not in the PBS + N, BPA-F + N, and BSA-10BPA + N groups, indicating that BNCT alone was insufficient to induce pyroptosis. The manganese in BSA-10BPA-MnO2 enhanced the oxidative stress induced by BNCT, leading to pyroptosis (Fig. 4b). To systematically evaluate specific pyroptosis markers, we assessed the expression of the cleaved form of caspase-1 (cleaved-CAS-1) and the N-terminal fragment of GSDMD (GSDMD-N) in tumor cells after different treatments using Western blotting and immunofluorescence staining. As shown in Fig. 4c and d, B16F10 cells treated with BSA-10BPA-MnO2 + N exhibited significantly upregulated expression of cleaved caspase-1 and GSDMD-N. In contrast, no significant changes were observed in the PBS + N, BPA-F + N, or BSA-10BPA + N groups. Since lactate dehydrogenase (LDH) is a typical marker of pyroptosis, we also measured LDH release from B16F10 cells after different treatments. Notably, the BSA-10BPA-MnO2 + N treatment group showed a significant increase in LDH release, with the LDH level in the culture medium being up to five times higher than the control, indicating clear evidence of pyroptosis in B16F10 cells (Fig. 4e). Biodistribution of BSA-10BPA-MnO2 in tumor-bearing mice Albumin-based drug delivery has become one of the key strategies in recent years for enhancing the tumor-targeting capabilities of drugs. This study builds on passive targeting via the EPR effect and combines it with the active targeting function of albumin to improve the delivery efficiency of the formulation and achieve enhanced in vivo anti-tumor effects. To investigate this, we established a subcutaneous B16F10 mouse model and used in vivo fluorescence imaging to study the targeting distribution of Cy5-labeled BSA-10BPA-MnO2. As shown in Fig. 5a and b, fluorescence signals appeared in the tumor as early as 1 h after intravenous injection of BSA-10BPA-MnO2. The signals peaked at 2 h and remained high at 4 h. Due to the liver’s biological filtration function, 30–99% of nanoparticles are blocked in the liver after systemic administration [45]. Even so, the tumor showed about two-thirds of the fluorescence intensity compared to the liver, indicating that BSA-10BPA-MnO2 has a high targeting affinity for tumors. Figures S8 and S9 also show that BSA-10BPA exhibits similar tumor targeting and affinity. In vivo Biodistribution of BSA-10BPA-MnO2 in Subcutaneous B16F10 Tumor-Bearing Mice. (a) Biodistribution of Cy5-labeled BSA-10BPA-MnO2 nanoparticles in subcutaneous B16F10 tumor-bearing mice, studied using IVIS Spectrum. (b) Quantification of average radiative efficiency in tumor and liver regions at different time points (n = 5). (c) 10B concentration in plasma, normal tissues, and tumors of B16F10 tumor-bearing mice after intravenous injection of BPA-F, BSA-10BPA, or BSA-10BPA-MnO2 (n = 3). (d) Tumor-to-blood (T/B) or tumor-to-normal (T/N) ratio in mice treated with BPA-F, BSA-10BPA, and BSA-10BPA-MnO2 (n = 3). Data are presented as mean ± SD Next, we quantitatively analyzed the distribution of BPA-F, BSA-10BPA, and BSA-10BPA-MnO2 in the B16F10 mouse model. Two hours after intravenous injection of these formulations, we measured the 10B concentration in plasma, normal tissues, and tumors using ICP-MS. As shown in Fig. 5c, the BPA-F group exhibited higher plasma 10B concentrations, but the tumor 10B concentration was the lowest at 5.34 µg/g. The tumor 10B concentrations in the BSA-10BPA and BSA-10BPA-MnO2 groups were 7.73 and 8.63 µg/g, respectively. Although these concentrations do not meet the clinical BNCT requirement of 20 µg/g (20 ppm), this study aims to develop a combined treatment approach of BNCT and immunotherapy. Further investigations will determine if BSA-10BPA-MnO2 can show effective anti-tumor effects even with lower tumor 10B concentrations. We then calculated the tumor-to-blood (T/B) and tumor-to-normal (T/N) ratios of 10B concentrations for each group (Fig. 5 d). As both BSA-10BPA and BSA-10BPA-MnO2 are nanoboron drugs, they exhibited better tumor retention compared to BPA-F, resulting in higher T/B and T/N ratios. This suggests that BSA-10BPA and BSA-10BPA-MnO2 not only provide the expected effective BNCT tumor therapy but also reduce the toxicity to normal tissues to some extent. Therefore, BSA-10BPA and BSA-10BPA-MnO2 are promising nanomedicines for boron neutron capture therapy. BSA-10BPA-MnO2enhances in vitro and in vivo T1-MRI imaging In the acidic pH and H2O2-rich microenvironment of tumors, MnO2 deposited on BSA-10BPA-MnO2 can release Mn2+, which significantly enhances T1-weighted MRI performance for tumor imaging. As shown in Fig. 6a, under in vitro simulated H2O2 conditions, the imaging intensity of BSA-10BPA-MnO2 solution increased with higher H2O2 concentrations, while the imaging intensity of BSA-10BPA (without Mn) solution showed no significant change. By calculating the longitudinal relaxation rate (1/T1) (Fig. 6b), the results showed that the relaxation rate of BSA-10BPA-MnO2 solution increased with higher H2O2 concentrations, while the relaxation rate of BSA-10BPA solution remained relatively unchanged, confirming the enhancement of T1-MRI imaging by Mn2+. The effect of BSA-10BPA-MnO2 on in vitro and in vivo T1-weighted MR signals. (a) T1 MR phantom images of BSA-10BPA-MnO2 (300 µM MnO2) and BSA-10BPA (equivalent BPA) after treatment with different concentrations of H2O2 (0, 50, 100, 150, 200, 300 µM). (b) The relationship between longitudinal relaxation rate (1/T1) and H2O2 (Mn2+) concentration. (c) In vivo dynamic MRI imaging after intravenous injection of DOTA-Gd or BSA-10BPA-MnO2. The dashed circle indicates the tumor region (150–200 mm³). (d) Quantification of tumor region image intensity at different time points from (c). Data are presented as mean ± SD After intravenously injecting the clinically used gadolinium-based MRI contrast agent Gadoteric acid (DOTA-Gd) or BSA-10BPA-MnO2 into B16F10 tumor-bearing mice, MRI images of the tumor region were taken at 0, 2, and 4 h (Fig. 6c). At 0 h (pre-injection), no significant difference was observed between DOTA-Gd and BSA-10BPA-MnO2. However, starting at 2 h post-injection, the MRI signals in the tumor region of both groups significantly increased and remained elevated until 4 h (Fig. 6 d). These results are consistent with the dynamic fluorescence signal changes of BSA-10BPA-MnO2 observed in vivo (Fig. 5a and b). Furthermore, compared to Gadoteric acid, BSA-10BPA-MnO2 showed a more pronounced enhancement of the tumor MRI signal (Fig. 6 d), indicating BSA-10BPA-MnO2 serves as a potential tool for MRI-guided BNCT, allowing imaging immediately prior to treatment to define the therapeutic window. BSA-10BPA-MnO2-induced DC maturation Dendritic cells (DCs) play a crucial role in effective anti-tumor immune responses. Mn2+ ions have been shown to induce DC maturation by activating the STING pathway. Flow cytometry analysis of bone marrow-derived dendritic cells (BMDCs) (Fig. 7a) indicated that BSA-10BPA-MnO2 did not affect CD80 expression on DCs. CD80 may be a more effective ligand for CD152 on effector T cells, and studies have suggested that CD152 can inhibit T cell activation and proliferation, thus playing a suppressive role in anti-tumor immunity [46]. In contrast, BSA-10BPA-MnO2 upregulated CD86 expression, an important marker of DC maturation and activation. CD86 is the dominant ligand for CD28 on effector T cells, and CD28 serves as a co-stimulatory molecule for T cell activation [46]. Therefore, BSA-10BPA-MnO2 selectively activates BMDCs by upregulating CD86 expression, which is crucial for initiating anti-tumor immune responses. BSA-10BPA-MnO2-induced dendritic cell (DC) maturation. (a) Flow cytometry detection of co-stimulatory molecules CD80 and CD86 expression on BMDCs. (b) Flow cytometry detection of co-stimulatory molecule CD40 expression on DCs in tumor-draining lymph nodes of B16F10 mice after different treatments. (c) Flow cytometry detection of the proportion of CD40+ DCs in tumor-draining lymph nodes of B16F10 mice after different treatments (n = 3). Data are presented as mean ± SD. *p < 0.5, ***p < 0.001 It has been shown that BSA-10BPA-MnO2 can effectively induce pyroptosis during the enhancement of BNCT. Pyroptosis is a highly immunogenic form of cell death that is accompanied by the release of damage-associated molecular patterns (DAMPs). DAMPs can bind to pattern recognition receptors on DCs, activating both innate and adaptive immunity [47]. To further assess the stimulatory effect of BSA-10BPA-MnO2-enhanced BNCT on DCs, we treated the B16F10 mouse model with different treatment groups, including PBS, BPA-F, BSA-10BPA, BSA-10BPA-MnO2, PBS + N, BPA-F + N, BSA-10BPA+N, and BSA-10BPA-MnO2 + N. Fourteen days post-treatment, we collected immune cells from the tumor-draining lymph nodes and performed flow cytometry analysis. As shown in Fig. 7b and c, the BNCT groups containing 10B-containing drugs (BPA-F + N, BSA-10BPA+N, BSA-10BPA-MnO2 + N) all showed an upregulation of CD40 expression. CD40 is another important marker of DC maturation and plays a key role in B cell proliferation and the initiation of effector T cell responses [48]. Therefore, BNCT can partially activate DCs in vivo. Notably, the BSA-10BPA-MnO2 + N group induced the strongest upregulation of CD40 expression, which we hypothesize is due to the multiple effects of Mn2+. Mn2+ can directly induce DC maturation through the STING pathway, while the Mn2+-mediated ROS storm after BNCT can cause pyroptosis and release DAMPs, further activating DCs. The activation of the cGAS-STING pathway was evaluated indirectly through DC maturation markers (CD80, CD86, CD40), as direct measurement of IFN-I secretion (e.g., by ELISA) was not feasible due to the 14-day follow-up period required for in vivo immune response assessment. This approach is supported by literature linking Mn2+ to STING activation [28, 29]. These results indicate that BSA-10BPA-MnO2 can trigger a stronger innate immune response during BNCT. BSA-10BPA-MnO2 enhances the anti-tumor immune response after BNCT Systemic immunity is essential for effective tumor immunotherapy [49]. Therefore, we investigated the activation of systemic immune responses after different treatments. A B16F10 melanoma mouse model was established by subcutaneously (s.c.) injecting 1 × 106 B16F10 cells into the right flank of C57BL/6 mice. When the tumor volume reached approximately 150 mm3, the mice were randomly divided into 8 groups (PBS, BPA-F, BSA-10BPA, BSA-10BPA-MnO2, PBS + N, BPA-F + N, BSA-10BPA+N, and BSA-10BPA-MnO2 + N). Immune analysis was performed on day 15 after treatment by isolating tumor-draining lymph nodes (TdLNs) and spleens. Flow cytometric analysis showed that none of the treatment groups caused a significant change in the proportion of CD4+ T cells (Figs. 8a and b). However, the BSA-10BPA-MnO2 + N treatment group induced a significantly higher proportion of cytotoxic CD8+ T cells in TdLNs compared to the other groups (Fig. 8a and c). Similarly, flow cytometric analysis revealed no significant change in the proportion of CD4+ T cells in the spleen (Fig. 8 d and e). All BNCT-treated groups (PBS + N, BPA-F + N, BSA-10BPA+N, and BSA-10BPA-MnO2 + N) showed an increase in cytotoxic CD8+ T cells, with the most significant increase observed in the spleens of the BSA-10BPA-MnO2 + N group (Fig. 8 d and f). These results suggest that BNCT treatment can induce a systemic anti-tumor immune response to some extent, with cytotoxic T cells (CD8+ T cells) playing a key role in anti-tumor activity. Among the groups, the BSA-10BPA-MnO2 + N group induced the strongest systemic immune activation, likely due to the multiple effects of Mn2+ release. BSA-10BPA-MnO2 enhances anti-tumor immune response after BNCT. (a) Flow cytometric analysis of CD4+ and CD8+ T cells (CD3+CD4+ and CD3+CD8+) in TdLNs from different treatment groups (n = 3). (b) The proportion of CD4+ T cells (CD3+CD4+) among mature T cells (CD3+) in TdLNs from different treatment groups (n = 3). (c) The proportion of CD8+ T cells (CD3+CD8+) among mature T cells (CD3+) in TdLNs from different treatment groups (n = 3). (d) Flow cytometric analysis of CD4+ and CD8+ T cells (CD3+CD4+ and CD3+CD8+) in the spleen from different treatment groups (n = 3). (e) The proportion of CD4+ T cells (CD3+CD4+) among mature T cells (CD3+) in the spleen from different treatment groups (n = 3). (f) The proportion of CD8+ T cells (CD3+CD8+) among mature T cells (CD3+) in the spleen from different treatment groups (n = 3). Data are expressed as mean ± SD. **p < 0.01, ***p < 0.001, ****p < 0.0001 BSA-10BPA-MnO2 enhances the in vivo therapeutic effect of BNCT After confirming the immune modulation effect of BSA-10BPA-MnO2 in BNCT, we evaluated its impact on enhancing the anti-tumor effects of BNCT in combination with immune therapy. As expected, the tumor growth in the BPA-F + N and BSA-10BPA+N groups was slower compared to the PBS + N group, which is attributed to the effective delivery of 10B enhancing the BNCT effect (Fig. 9a and b). The BSA-10BPA-MnO2 + N group showed the best tumor growth inhibition, likely due to the significant improvement in immune activation from the manganese loading. Although group 8 (BSA-10BPA-MnO2 + N) showed higher inter-animal variability in tumor growth, the overall reduction was significant, confirming the robust therapeutic effect. The mouse weight curve preliminarily demonstrated the safety of this treatment strategy (Fig. 9c). Hematoxylin and eosin (H&E) staining, along with TUNEL staining, showed that the BSA-10BPA-MnO2 + N group induced the most tumor cell death, which correlated with the observed tumor suppression (Figs. 9d and e). Ki67 immunohistochemical staining also revealed that highly proliferative tumor cells were significantly reduced after BSA-10BPA-MnO2-enhanced BNCT treatment (Fig. 9f). In summary, BSA-10BPA-MnO2-enhanced BNCT in combination with immune therapy significantly improves the treatment efficacy of B16F10 melanoma compared to BNCT alone. BSA-10BPA-MnO2 enhances the in vivo therapeutic effect of BNCT. (a) Tumor growth curves for different treatment groups. Tumor volume was monitored every 2 days (n = 8). (b) Individual tumor growth in each group after different treatments (n = 8). (c) Body weight change curves for different treatment groups (n = 8). (d) H&E staining of tumor tissues from different treatment groups. Scale bar: 100 μm. (e) TUNEL immunofluorescence staining of tumor tissues from different treatment groups. Scale bar: 100 μm. (f) Ki67 immunohistochemical staining of tumor tissues from different treatment groups. Scale bar: 100 μm. Data are presented as mean ± SD Biosafety analysis The biosafety of different treatment groups was evaluated in tumor-bearing mice. Notably, there was no significant weight loss in any of the groups during the treatment period (Fig. 9c). Histological examination of major organs, including the heart, liver, spleen, lungs, and kidneys, showed no obvious inflammatory infiltration or side effects in any treatment group. This suggests that the local BNCT treatment strategy is safe. Additionally, renal function biomarkers, including creatinine (CREA) and blood urea nitrogen (BUN), as well as liver function biomarkers such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum alkaline phosphatase (ALP), were assessed to evaluate the systemic toxicity of the multifunctional boron nanoparticles. The results indicated that all serum biochemical markers remained within normal levels (Figure S10). In summary, these data confirm the biosafety of BSA-10BPA-MnO2-enhanced BNCT in combination with immune therapy in vivo. Conclusion In summary, we developed BSA-10BPA-MnO2, a tumor microenvironment-responsive, manganese-enriched nanoboron agent that effectively addresses key limitations of conventional BNCT—namely, therapy-induced immunosuppression and limited synergy with immunotherapy. By integrating Fenton-like catalytic activity and cGAS-STING pathway activation into a single nanosystem, this platform reprograms BNCT from a local radiotherapy into a systemically immune-potentiating treatment. Mechanistically, the released Mn2+ amplifies BNCT-induced oxidative stress and triggers immunogenic pyroptosis, while simultaneously activating innate immune signaling and enhancing dendritic cell maturation. These effects collectively prime robust CD8+ T cell-mediated anti-tumor immunity. Notably, these therapeutic outcomes were achieved even at boron concentrations below the traditional clinical threshold, underscoring the system’s capacity to overcome dose-dependency through immune amplification. In addition, BSA-10BPA-MnO2 facilitates MRI-guided precision treatment, integrating diagnostic imaging with therapeutic delivery. Together, these findings position BSA-10BPA-MnO2 as a next-generation BNCT agent with enhanced immunotherapeutic synergy and translational potential for solid tumor treatment, particularly melanoma. Experimental section Materials Bovine serum albumin (BSA) was purchased from Sigma-Aldrich (Shanghai, China). Glutaraldehyde, sodium hydroxide (NaOH), phosphate-buffered saline (PBS), and analytical-grade methanol were obtained from Sinopharm Chemical Reagent Co., Ltd. (China) and Beijing Bailingwei Technology Co., Ltd. (China). 10B-enriched 4-borono-L-phenylalanine (10BPA) was supplied by Guangdong Dongyangguang Pharmaceutical Co., Ltd. (China). Fructose was obtained from Aladdin Biochemical Technology Co. (Shanghai, China). Cy5-NHS ester was purchased from Duofluor Inc. (China). Dulbecco’s Modified Eagle Medium (DMEM, high glucose) was obtained from Procell Life Science & Technology Co., Ltd. (Wuhan, China). Fetal bovine serum (FBS) was sourced from Thermo Fisher Scientific (USA). Penicillin–streptomycin (100×) and 0.25% trypsin–EDTA solution were purchased from Meilunbio (Dalian, China). Cell Counting Kit-8 (CCK-8) was obtained from BOGOO Biotechnology Co., Ltd. (Dalian, China). Antibodies used for flow cytometry included FITC-conjugated anti-CD45, PerCP/Cy5.5-conjugated anti-CD3, APC-conjugated anti-CD4, PE-conjugated anti-CD8a, Pacific Blue-conjugated anti-CD80, PE-conjugated anti-CD40, PE/Cy7-conjugated anti-CD86, and APC-conjugated anti-CD11c (BioLegend China, Beijing, China). Anti-GSDMD N-terminal antibody was purchased from Affinity Biosciences (China), and anti-cleaved caspase-1 antibody was obtained from MedChemExpress (MCE, China). Reactive oxygen species (ROS) probe DCFH-DA and lactate dehydrogenase (LDH) assay kits were purchased from Beyotime Biotechnology (China). Synthesis of BSA-F, BSA-10BPA and BSA-10BPA-MnO2 Preparation of BPA-fructose complex (BPA-F): 10B-enriched 4-borono-L-phenylalanine (10BPA) was dissolved in deionized water, and the pH was adjusted to above 10 using 0.1 M NaOH under stirring. An equimolar amount of fructose was then added, and the solution was stirred continuously under alkaline conditions until complete dissolution. The pH was subsequently adjusted to 7.4, and the solution was filtered through a 0.22 μm membrane to remove undissolved residues. Synthesis of BSA-10BPA nanoparticles: To prepare albumin-boron nanoparticles (BSA-10BPA), 100 mg of bovine serum albumin (BSA) was dissolved in 2 mL of deionized water with pH adjusted to 8.5 using 0.1 M NaOH. In parallel, 20 mg of 10BPA was dissolved in 10 mL of methanol by heating at 80 °C for 10 min followed by sonication for 5 min. If necessary, the heating-sonication cycle was repeated until the solution was clear. The BPA-methanol solution (8 mL total volume) was added dropwise to the BSA solution at a rate of 0.6 mL/min using a syringe pump under vigorous stirring (1000 rpm). After complete addition, 100 µL of 8% (v/v) glutaraldehyde was added to the mixture for crosslinking, and the reaction was allowed to proceed at room temperature under moderate stirring (800 rpm) for 12 h. Methanol was then removed by rotary evaporation. The resulting nanoparticle suspension was centrifuged to remove unbound 10BPA and dialyzed (MWCO: 8–14 kDa) against deionized water for 48 h to eliminate residual glutaraldehyde. Synthesis of BSA-10BPA-MnO2 nanoparticles: To prepare BSA-10BPA-MnO2 nanoparticles, 5 mL of 1.05 mg/mL KMnO4 solution was added dropwise to freshly prepared BSA-BPA nanoparticle solution at 37 °C under vigorous stirring. The reaction was incubated for 30 min to allow MnO2 deposition onto the nanoparticle surface. The product was dialyzed extensively to remove free KMnO4 and stored at 4 °C for further use. Fluorescent labeling with Cy5: For in vivo imaging studies, BSA-10BPA or BSA-10BPA-MnO2 nanoparticles were fluorescently labeled with Cy5-NHS. Briefly, 200 µL of Cy5-NHS solution (5 mg/mL in DMSO) was added to the BSA-10BPA or BSA-10BPA-MnO2 suspension and incubated for 1 h at room temperature in the dark. The labeled nanoparticles were purified by dialysis to remove unreacted dye and stored in the dark at 4 °C. Characterization of nanoparticles The physicochemical properties of BSA-10BPA and BSA-10BPA-MnO₂ nanoparticles were systematically characterized. The hydrodynamic size and polydispersity index (PDI) were measured by dynamic light scattering (DLS) using an Anton paar litesizer 500 (AUSTRIA). The ζ potential of each formulation was also recorded with the same instrument to evaluate surface charge and colloidal stability. Transmission electron microscopy (TEM) was used to observe nanoparticle morphology. Samples were deposited onto carbon-coated copper grids, air-dried, and imaged using a JEM-2100 TEM (JEOL Ltd., Japan) operated at 200 kV. X-ray diffraction (XRD) patterns were collected on an Empyrean diffractometer (Malvern Panalytical Ltd., China) using an Ag Kα radiation source (energy: 22.1 keV; λ = 0.560885 Å). The diffraction angle (2θ) was scanned from 3° to 90°, corresponding to a maximum scattering vector of Q_max = 21.35 Å⁻¹, to analyze the crystalline structure of BSA, BSA-10BPA, and BSA-10BPA-MnO2. X-ray photoelectron spectroscopy (XPS) was conducted using an ESCALAB 250Xi spectrometer (Thermo Fisher Scientific, USA) to examine the elemental composition and chemical states of BSA-10BPA-MnO₂. High-resolution spectra were acquired for B 1 s, C 1 s, N 1 s, O 1 s, and Mn 2p. Ultraviolet–visible (UV-Vis) absorption spectra were recorded using a UV-2450 spectrophotometer (Shimadzu, Japan). To assess the H2O2-responsive degradability of the MnO2 shell, BSA-10BPA-MnO2 nanoparticles (300 µM MnO2 equivalent) were pretreated with varying concentrations of H2O2 (0, 50, 100, 150, 200, and 300 µM) under mildly acidic conditions (pH ≈ 6.8), and absorbance changes were monitored. Cell lines The murine melanoma cell line B16F10 and the human glioblastoma cell line U87-MG were obtained from Beina Chuanglian Biotechnology Institute (Beijing, China). Both cell lines were cultured in complete Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin. Cells were maintained at 37 °C in a humidified incubator with 5% CO2. Intracellular boron uptake B16F10 (n = 4 per group) and U87-MG (n = 3 per group) cells were seeded in 6-well plates at a density of 2 × 105 cells per well and incubated overnight. Cells were then treated with BPA-F, BSA-10BPA, or BSA-10BPA-MnO2 (equivalent 10B concentration: 25 µg/mL) for 4 h at 37 °C. After incubation, cells were washed with PBS, harvested, and digested in a mixture of concentrated nitric acid and 30% hydrogen peroxide (3:1, v/v) at 80 °C for 2 h. The resulting solutions were diluted with ultrapure water, filtered (0.22 μm), and analyzed using inductively coupled plasma mass spectrometry (ICP-MS) to quantify intracellular 10B content. Cell viability assay B16F10 (n = 6 per group) and U87-MG (n = 4 per group) cells were seeded in 96-well plates at 5 × 103 cells per well. After 24 h, cells were exposed to different concentrations of BPA-F, BSA-10BPA, or BSA-10BPA-MnO2 for 24 h. Cell viability was evaluated using the Cell Counting Kit-8 (CCK-8, BOGOO Biotechnology, China), and absorbance at 450 nm was measured with a microplate reader. Cell viability was expressed as a percentage relative to untreated controls. Neutron irradiation protocol and dose specification Cells and mice were irradiated using the accelerator-based BNCT system NeuPex (https://en.neuboron.com/products) developed by Neuboron Therapy System Ltd., in Xiamen, China. The neutron accelerator voltage is 2.3 MeV, and the current is 7 mA. The cells or mice were fixed in the corresponding holder while the holder was mounted into the irradiation port for irradiation. The cell holder as well as the mouse holding device were carefully designed to provide a uniform, low-contamination, high-intensity thermal neutron field to the targets. Shielding was used to limit irradiation to the tumor region, avoiding whole-body exposure. In this study, the neutron radiation dose for both in vitro and in vivo BNCT using the accelerator neutron source was 1 Gy. The 1 Gy dose refers to the physical absorbed dose (1 Gy = 1 J/kg) delivered by the neutron beam, which is a standard dose used in preclinical BNCT studies to balance efficacy and safety. This dose represents the total absorbed dose from neutron irradiation, including contributions from photons and fast neutrons, but without boron capture effects. The boron-specific dose is calculated separately based on 10B concentration. Colony formation assay following BNCT (B16F10) To evaluate the therapeutic effect of BNCT, B16F10 (n = 3 per group) cells were treated with the above formulations for 4 h and washed thoroughly with PBS. Neutron irradiation was performed at a physical dose of 1 Gy using an accelerator-based epithermal neutron source at the BNCT Center of Neuboron Medtech Ltd. (Xiamen, China). After irradiation, cells were reseeded into 6-well plates (500 cells/well) and cultured for 10 days. Colonies were fixed with 4% paraformaldehyde, stained with 0.1% crystal violet, and quantified. The colony count was used to assess the clonogenic survival fraction after BNCT. Reactor-based BNCT validation (U87-MG) To further assess the boron neutron capture effect in human glioblastoma cells, U87-MG cells were treated similarly and were neutron-irradiated for 0, 15, 30, 45 min at 1 MW with a thermal neutron beam at the Kyoto University Research Reactor (KUR), Heavy Water Neutron Irradiation Facility. Colony formation assays were conducted as described above. The extent of colony inhibition served as a measure of BNCT efficacy under reactor-based neutron exposure. Intracellular ROS detection B16F10 cells were seeded into 24-well plates and incubated with PBS, BPA-F, BSA-10BPA, or BSA-10BPA-MnO2 for 4 h, followed by neutron irradiation (1 Gy, Neuboron Medtech Xiamen BNCT Center). After 24 h, intracellular reactive oxygen species (ROS) levels were evaluated using DCFH-DA (10 µM, Beyotime Biotechnology, China). Cells were incubated with DCFH-DA for 30 min at 37 °C, washed with PBS, and imaged using a fluorescence microscope (Leica TCS SP8, Germany). Scale bar: 150 μm. Cell morphology observation Post-treatment morphological changes were observed using bright-field microscopy. Notably, in the BSA-10BPA-MnO2 + BNCT group, pyroptosis-like features such as cellular swelling and large membrane bubbles (indicated by blue arrows) were evident. Images were acquired with a high-resolution inverted microscope. Western blot analysis of caspase-1 activation Protein expression levels of caspase-1 and cleaved caspase-1 were assessed by Western blotting. Treated B16F10 cells were lysed using RIPA buffer containing protease inhibitors. Equal amounts of total protein were separated by SDS-PAGE and transferred onto PVDF membranes. After blocking, membranes were probed with primary antibodies against caspase-1 and cleaved caspase-1 (MedChemExpress, China), followed by HRP-conjugated secondary antibodies. Protein bands were visualized using an ECL detection system. Immunofluorescent staining of GSDMD-N To detect pyroptosis execution, immunofluorescent staining was performed to visualize the N-terminal fragment of gasdermin D (GSDMD-N). Cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and incubated with anti-GSDMD-N antibody (Affinity Biosciences, China), followed by fluorophore-conjugated secondary antibody. Nuclei were counterstained with DAPI. Images were acquired using a confocal microscope (Leica TCS SP8, Germany). Scale bar: 100 μm. Lactate dehydrogenase (LDH) release assayLact Cell membrane rupture was assessed by quantifying LDH release using a commercial LDH assay kit (Beyotime Biotechnology, China), following the manufacturer’s protocol. B16F10 cells were treated as described above (n = 4 per group), and the absorbance of LDH release was measured at 490 nm using a microplate reader. Data were normalized to maximum lysis controls and expressed as relative LDH release. Mice and animal models Male C57BL/6 mice (6 weeks old) and BALB/c nude mice (6 weeks old) were purchased from Slaccas Laboratory Animal Co., Ltd. (Shanghai, China) and acclimated for at least one week under specific pathogen-free (SPF) conditions. All mice were housed in a temperature- and humidity-controlled environment (22 ± 2 °C, 55 ± 5% humidity) with a 12 h light/dark cycle and had free access to food and water. All animal procedures were carried out in accordance with the Guidelines for the Care and Use of Laboratory Animals and were approved by the Animal Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine (Approval No. AIRB-2024-2064). Subcutaneous B16F10 melanoma model To establish the subcutaneous melanoma model, 1 × 106 B16F10 murine melanoma cells suspended in 100 µL of sterile PBS were injected subcutaneously into the right flank of male C57BL/6 mice. Tumor growth was monitored every other day using digital calipers, and tumor volume was calculated using the formula: Tumor volume = (length × width2)/2. Subcutaneous U87-MG glioblastoma model For the human glioblastoma xenograft model, 1 × 106 U87-MG cells in 100 µL PBS were injected subcutaneously into the right flank of immunodeficient BALB/c nude mice (6 weeks old, purchased from Slaccas, Shanghai, China). Tumor size was monitored as above. Fluorescence imaging To evaluate the biodistribution of BSA-10BPA-MnO2 nanoparticles in vivo, Cy5-labeled BSA-10BPA-MnO2 was intravenously injected into B16F10 tumor-bearing C57BL/6 mice (tumor volume ~ 100 mm3, n = 5 per group). At predetermined time points (2, 4, 8, and 24 h post-injection), whole-body fluorescence imaging was performed using an IVIS Spectrum imaging system (PerkinElmer, USA). The fluorescence signal in the tumor, liver, and other major organs was quantitatively analyzed using Living Image software, and average radiant efficiency (photons/sec/cm2/sr)/(µW/cm2) was calculated to assess nanoparticle accumulation. Boron biodistribution by ICP-MS To quantify 10B distribution, mice were intravenously administered BPA-F, BSA-10BPA, or BSA-10BPA-MnO2 (equivalent 10B dose: 25 mg/kg). At 2 h post-injection, mice (n = 3 per group) were euthanized, and blood, normal tissue, and tumors were harvested. Tissues were weighed, digested in a mixture of concentrated nitric acid and hydrogen peroxide (3:1, v/v) at 80 °C for 2 h, diluted with ultrapure water, and filtered through 0.22 μm membranes. The 10B content in each sample was quantified using inductively coupled plasma mass spectrometry (ICP-MS). Boron concentrations were expressed as µg 10B per gram of tissue or per mL of plasma. Tumor-to-Blood and Tumor-to-Normal tissue ratios To evaluate boron selectivity, tumor-to-blood (T/B) and tumor-to-normal tissue (T/N) ratios were calculated based on the ICP-MS results for each formulation. Higher T/B and T/N ratios were indicative of better tumor-targeted boron delivery, which is essential for effective BNCT. In vitro T1 MR Phantom imaging To assess the H2O2-responsive magnetic resonance (MR) contrast behavior of BSA-10BPA-MnO2, nanoparticle solutions (300 µM MnO2 equivalent) were pretreated with various concentrations of hydrogen peroxide (0, 50, 100, 150, 200, and 300 µM) under mildly acidic conditions (pH ≈ 6.8) for 30 min. Samples were then transferred to 0.5 mL Eppendorf tubes and embedded in a 1% agarose matrix for imaging. T1-weighted phantom images were acquired using a 7.0 T small animal MRI system (PharmaScan 7016, Bruker Biospin GmbH, Germany). Imaging parameters were as follows: repetition time (TR) = 500 ms, echo time (TE) = 10 ms, slice thickness = 1 mm, field of view (FOV) = 30 × 30 mm2. The longitudinal relaxation rate (1/T1) was measured for each sample, and its correlation with H2O2 (i.e., Mn2+ release) concentration was plotted. In vivo MRI imaging B16F10 tumor-bearing C57BL/6 mice (tumor volume ~ 150–200 mm3) were intravenously injected with either BSA-10BPA-MnO2 or the clinical contrast agent DOTA-Gd (both equivalent to 0.1 mmol Mn or Gd per kg). T1-weighted MR images were collected before injection (baseline) and at 0.5, 1, 2, and 4 h post-injection. Imaging was performed on the same Bruker 7.0 T MRI system using a T1-weighted spin echo sequence (TR = 400 ms, TE = 9 ms). The tumor region was outlined manually (dashed circle), and signal intensity was quantified using Bee DICOM Viewer software. In vitro BMDC maturation assay Bone marrow-derived dendritic cells (BMDCs) were generated from femurs and tibias of C57BL/6 mice. Bone marrow cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 20 ng/mL GM-CSF, and 10 ng/mL IL-4 for 6 days, with medium refreshed every 2 days. On day 6, immature BMDCs were treated with BSA-10BPA-MnO2 nanoparticles (equivalent 10B concentration: 25 µg/mL) for 24 h. After treatment, cells were harvested and stained with fluorophore-conjugated antibodies against CD11c, CD80, and CD86 (BioLegend, China) for 30 min at 4 °C in the dark. After washing with PBS containing 2% FBS, cells were analyzed by flow cytometry using a CytoFLEX S flow cytometer (Beckman Coulter, USA). Expression levels of CD80 and CD86 on CD11c+ BMDCs were quantified. In vivo DC maturation in Tumor-Draining lymph nodes To evaluate DC activation in vivo, B16F10 tumor-bearing mice were treated with PBS, BPA-F, BSA-10BPA, or BSA-10BPA-MnO2, neutron irradiation (1 Gy, Xiamen BNCT Center) was performed 4 h after intravenous injection to maximize tumor boron accumulation based on biodistribution data. 14 day post-treatment, tumor-draining inguinal lymph nodes were harvested, mechanically dissociated, and filtered through a 70 μm cell strainer to obtain single-cell suspensions. Cells were stained with antibodies against CD11c and CD40 (BioLegend, China) and analyzed on a CytoFLEX S flow cytometer. The proportion of CD40+ DCs (CD11c+CD40+) was calculated using FlowJo software. BSA-10BPA-MnO2 enhances Anti-Tumor immune response after BNCT To investigate immune activation following BNCT, B16F10 tumor-bearing C57BL/6 mice were intravenously injected with PBS, BPA-F, BSA-10BPA, or BSA-10BPA-MnO2 (equivalent 10B: 25 mg/kg), followed by neutron irradiation (1 Gy, Xiamen BNCT Center). 14 days after treatment, mice were euthanized, and tumor-draining lymph nodes (TdLNs) and spleens were harvested. Single-cell suspensions were prepared by mechanical dissociation and filtration through a 70 μm strainer. Red blood cells in spleen samples were lysed using ACK lysis buffer. Cells (n = 3 per group) were stained with fluorophore-conjugated antibodies against CD3, CD4, and CD8 (BioLegend, China) for 30 min at 4 °C in the dark. After washing, samples were analyzed by flow cytometry using a CytoFLEX S flow cytometer (Beckman Coulter, USA). The percentages of CD4+ (CD3+CD4+) and CD8+ (CD3+CD8+) T cells were quantified in both TdLNs and spleen. Data were processed using FlowJo software. Tumor growth Inhibition study B16F10 tumor-bearing mice (~ 150 mm3 tumor volume) were randomly divided into groups (n = 8) and intravenously injected with PBS, BPA-F, BSA-10BPA, or BSA-10BPA-MnO2, mice were intravenously injected with BPA-F, BSA-10BPA, or BSA-10BPA-MnO2 at an equivalent 10B dose of 25 mg/kg. Four hours post-injection, mice received neutron irradiation (1 Gy). Tumor size and body weight were measured every 2 days. Tumor volume was calculated using the formula: Volume = (length × width2)/2. Growth curves and individual tumor progression were plotted to assess therapeutic efficacy and variability. Histological and immunostaining analyses At day 14 post-treatment, tumor tissues were collected, fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned (5 μm). For histological evaluation, sections were stained with hematoxylin and eosin (H&E) and imaged under a bright-field microscope. Apoptotic cells were assessed by TUNEL staining using a commercial assay kit, and proliferation was evaluated via Ki-67 immunohistochemical (IHC) staining. Images were acquired with a high-resolution digital microscope, and representative fields were presented (scale bar: 100 μm). Body weight monitoring Body weight of mice was recorded every two days during and after treatment as a general indicator of physiological tolerance and potential systemic toxicity. Histopathological evaluation At the end of the therapeutic experiment (typically day 14 post-BNCT), major organs including the heart, liver, spleen, lungs, and kidneys were collected, fixed in 4% paraformaldehyde, embedded in paraffin, sectioned (5 μm), and stained with hematoxylin and eosin (H&E). Histological changes were examined under a light microscope to assess possible organ damage, inflammatory infiltration, or histopathologic abnormalities. Serum biochemical analysis Blood samples for serum biochemistry were collected from n = 3 mice per group via the retro-orbital sinus, as this sample size yields reliable data for metabolic markers while reducing animal numbers. After collection, centrifugation was performed to separate serum. Renal function markers—creatinine (CREA) and blood urea nitrogen (BUN)—and hepatic function indicators—alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP)—were measured using an automated biochemical analyzer. All values were compared to reference normal ranges to evaluate potential treatment-related organ toxicity. Statistics Statistical analysis was performed using GraphPad Prism 8 (GraphPad Software, CA, USA). Data were presented as means ± S.D. Statistical evaluation of differences between experimental groups was performed by one-way ANOVA followed by Tukey’s multiple comparisons test. Statistical significance was considered at least at p < 0.05. Supplementary Information Supplementary Material 1. Acknowledgements We thank Mengjie Yu at Bio-Ultrastructure Analysis Lab. of Analysis Center of Agrobiology and Environmental Sciences, Zhejiang University for her technical assistance on transmission electron microscopy; Jianyang Pan (Research and Service Center, College of Pharmaceutical Sciences, Zhejiang University) for performing NMR spectrometry for structure elucidation; Yingying Huang at Zhejiang University School of Medicine for her technical assistance on flow cytometry; Qin Han, Chenyu Yang and Dandan Song at the Center of Cryo-Electron Microscopy (CCEM), Zhejiang University for their technical assistance on confocal laser scanning microscopy and transmission electron microscopy; Junli Xuan and Yanwei Li at the Core Facilities of Zhejiang University School of Medicine for technical assistance of confocal laser scanning microscopy and flow cytometry analysis; Lijuan Mao, Chaogang Xin and Dongmei Qi at Analysis Center of Agrobiology and Environmental Sciences, Zhejiang University for their technical assistance on FT-IR, XRD, and DSC; Jianyang Pan and Dan Wu at Research and Science Center, College of Pharmaceutical Sciences, Zhejiang University for their technical assistance on HPLC; Ya Xie at College of Biosystems Engineering and Food Science, Zhejiang University for her technical assistance on rheological measurements. Author contributions Qichun Wei, DongHang Xu and Min Han conceived the project and designed the experiments. Qichun Wei, DongHang Xu and Min Han supervised the project, discussed and commented on the manuscript. Zhicheng Zhang performed the experiments and data analysis. Zhicheng Zhang wrote the manuscript. Xiaoyan Sun, Yaxin Qin, Qi Dai, Xiaoyan Bao, Minoru Suzuki, Sheng Wang, Zai Yang and Zhifeng Li proofread the manuscript. All authors read and approved the final manuscript. Funding This work was supported by the National Key Research and Development Program of China (No. 2023YFA1008600, No. 2024YFA1613800, No. 2022YFE0107800), the National Natural Science Foundation of China (No. 82373206). Data availability All data generated or analysed during this study are included in this published article. Declarations Ethics approval and consent to participate The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Animal Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine (Approval No. AIRB-2024-2064). Written informed consent was obtained from individual or guardian participants. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Min Han, Email: hanmin@zju.edu.cn. Donghang Xu, Email: xudonghang@zju.edu.cn. Qichun Wei, Email: qichun_wei@zju.edu.cn. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement All data generated or analysed during this study are included in this published article.